Trade name was Brintellex, now Trintellix.
Oral agent atypical antidepressant with bioavailability of 75% which peaks at 7–11 hours.
A selective serotonin reuptake inhibitor.
Has a protein binding of 98%.
Metabolism is by extensive hepatic, primarily by CYP2D6-mediated oxidation.
Associated with a half-life of 66 hours.
Excretion is 59% in the urine, and 26% in feces.
Approved for the treatment of major depressive disorder (MDD) in adults.
Also used as a treatment for generalized anxiety disorder.
Superiority of 5 mg doses of vortioxetine over placebo.
Available as 5 mg, 10 mg, and 20 mg tablets, with 10 mg per day the recommended starting dose.
The most common side effects are nausea, diarrhea, xerostomia, constipation, vomiting, flatulence, dizziness, and sexual dysfunction.
Better tolerated than other antidepressants.
Vortioxetine used alone in high dose or in combination with other antidepressants, can produce the serotonin syndrome.
A serotonin reuptake inhibitor (SRI), and a Norepinephrine transporter (NET) blocker.
Iindicated for the treatment of major depressive disorder (MDD) and is supplied in 5 mg, 10 mg, 15 mg and 20 mg tablets.
Steady-state plasma concentrations usually are reached within two weeks.
Absorption not affected by food intake.
Has no active metabolites.
Initiated drug therapy at 10 mg daily, which may be subsequently increased to 20 mg daily.
Can be discontinued abruptly, however it is recommended that doses be tapered when discontinuing the drug.
In CYP2D6 poor metabolizes the maximum recommend dose is 10 mg/day.
Should not be used concomitantly with an MAOI.
The most commonly observed adverse reactions are nausea, constipation, and vomiting.